EDIT
Price
$1.64
Change
+$0.15 (+10.07%)
Updated
May 20 closing price
Capitalization
137.29M
70 days until earnings call
NVAX
Price
$7.68
Change
-$0.06 (-0.78%)
Updated
May 20 closing price
Capitalization
1.24B
77 days until earnings call
Interact to see
Advertisement

EDIT vs NVAX

Header iconEDIT vs NVAX Comparison
Open Charts EDIT vs NVAXBanner chart's image
Editas Medicine
Price$1.64
Change+$0.15 (+10.07%)
Volume$2.38M
Capitalization137.29M
Novavax
Price$7.68
Change-$0.06 (-0.78%)
Volume$23M
Capitalization1.24B
EDIT vs NVAX Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. NVAX commentary
May 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 21, 2025
Stock price -- (EDIT: $1.64 vs. NVAX: $7.68)
Brand notoriety: EDIT: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 121% vs. NVAX: 245%
Market capitalization -- EDIT: $137.29M vs. NVAX: $1.24B
EDIT [@Biotechnology] is valued at $137.29M. NVAX’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $292.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 7 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 7 bullish, 3 bearish.
  • NVAX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than NVAX.

Price Growth

EDIT (@Biotechnology) experienced а +9.33% price change this week, while NVAX (@Biotechnology) price change was +24.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.03%. For the same industry, the average monthly price growth was +12.52%, and the average quarterly price growth was -1.77%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.24B) has a higher market cap than EDIT($137M). EDIT YTD gains are higher at: 29.134 vs. NVAX (-4.478). NVAX has higher annual earnings (EBITDA): -108.04M vs. EDIT (-233.11M). NVAX has more cash in the bank: 923M vs. EDIT (270M). EDIT has less debt than NVAX: EDIT (35M) vs NVAX (230M). NVAX has higher revenues than EDIT: NVAX (682M) vs EDIT (32.3M).
EDITNVAXEDIT / NVAX
Capitalization137M1.24B11%
EBITDA-233.11M-108.04M216%
Gain YTD29.134-4.478-651%
P/E RatioN/A2.79-
Revenue32.3M682M5%
Total Cash270M923M29%
Total Debt35M230M15%
FUNDAMENTALS RATINGS
EDIT vs NVAX: Fundamental Ratings
EDIT
NVAX
OUTLOOK RATING
1..100
2323
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
6349
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for NVAX (87). This means that EDIT’s stock grew somewhat faster than NVAX’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

EDIT's SMR Rating (95) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (49) in the Biotechnology industry is in the same range as EDIT (63). This means that NVAX’s stock grew similarly to EDIT’s over the last 12 months.

NVAX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that NVAX’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNVAX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIIEX41.380.19
+0.46%
American Funds Intl Gr and Inc R2E
MVGJX17.780.04
+0.23%
MFS Low Volatility Global Equity R1
IAVGX19.71N/A
N/A
Voya Growth and Income Port A
PDSIX44.79N/A
N/A
PGIM Quant Solutions Large-Cap Index I
PEDMX13.10N/A
N/A
Principal Edge MidCap R6

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-0.78%
MRNA - NVAX
46%
Loosely correlated
+6.06%
BNTX - NVAX
42%
Loosely correlated
+4.01%
THRD - NVAX
42%
Loosely correlated
-0.19%
FHTX - NVAX
41%
Loosely correlated
-1.66%
ARCT - NVAX
41%
Loosely correlated
+5.92%
More